Back to VVUS Stock Lookup
Pages: 1 2 3 »» Last Page

VIVUS (VVUS) – Company Press Releases

Dec 11, 2020 04:49 PM VIVUS Receives Court Approval of Joint Chapter 11 Plan of Reorganization
Nov 13, 2020 08:30 PM VIVUS Seeks Bankruptcy Court Approval of Second Amended Joint Chapter 11 Plan of Reorganization and Existing Stock Record Date
Jul 7, 2020 04:49 PM VIVUS Completes Solicitation for In-Court Reorganization Plan to Become a Wholly Owned Subsidiary of IEH Biopharma LLC
Jun 2, 2020 07:30 AM VIVUS Announces Updated Agreement with Icahn Enterprises Holdings L.P.
May 6, 2020 04:05 PM VIVUS Reports First Quarter 2020 Financial Results
May 1, 2020 08:40 AM VIVUS to Host First Quarter Business Update and Financial Results Conference Call on Wednesday, May 6, 2020
May 1, 2020 08:35 AM VIVUS Announces Agreement with IEH Biopharma LLC Granting the Company a 30-Day Grace Period to Restructure its Corporate Debt
Apr 3, 2020 03:00 PM VIVUS Announces Closing of $11.55 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
Apr 3, 2020 08:00 AM VitalTech Partners with VIVUS Pharmaceuticals to Accelerate Launch of Telehealth and Remote Patient Monitoring Modules
Apr 1, 2020 09:02 AM VIVUS Announces $11.55 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
Mar 31, 2020 07:30 AM VIVUS Accelerates the Launch of Telemedicine and Remote Monitoring Modules to Facilitate Effective Patient Care During “Social Distancing”
Mar 3, 2020 04:05 PM VIVUS Reports Fourth Quarter and Full Year 2019 Financial Results
Mar 2, 2020 07:30 AM VIVUS Completes Enrollment in Phase 4 Safety and Efficacy Study of Qsymia® in Adolescents
Feb 19, 2020 07:30 AM VIVUS Announces Commercial Launch of Qsymia® in the Republic of Korea Establishing New Royalty Revenue Stream
Feb 18, 2020 07:30 AM VIVUS to Host Fourth Quarter Business Update and Financial Results Conference Call on Tuesday, March 3, 2020
Feb 5, 2020 07:30 AM VIVUS Receives U.S. Food and Drug Administration Approval for Improved Formulation of PANCREAZE® with a 36-Month Shelf Life
Feb 5, 2020 07:30 AM VIVUS Receives U.S. Food and Drug Administration Approval for Improved Formulation of PANCREAZE® with a 36-Month Shelf Life
Jan 7, 2020 07:30 AM New Data Further Demonstrate Effectiveness of VIVUS’ Qsymia as a Weight Management Tool
Jan 2, 2020 07:30 AM VIVUS to Present at Biotech Showcase on January 13, 2020
Dec 31, 2019 07:30 AM VIVUS Adopts Stockholder Rights Plan
Dec 18, 2019 07:30 AM VIVUS Announces New Data Supporting the Safety and Efficacy of Qsymia® in Adolescents with Obesity
Nov 25, 2019 07:30 AM VIVUS to Present at Piper Jaffray 31st Annual Healthcare Conference on December 3, 2019
Nov 20, 2019 07:30 AM New Clinical Data Demonstrate VIVUS’ Qsymia® is Effective at Reducing Binge Eating in Patients with Binge-Eating Disorder or Bulimia Nervosa
Nov 5, 2019 04:05 PM VIVUS Reports Third Quarter 2019 Financial Results
Oct 28, 2019 07:30 AM VIVUS Announces Departures of Eric W. Roberts and Allan L. Shaw from Board of Directors
Oct 22, 2019 07:30 AM VIVUS to Host Third Quarter Business Update and Financial Results Conference Call on Tuesday, November 5, 2019
Oct 21, 2019 07:30 AM VIVUS to Highlight Integrated Approach to More Effective Weight Management in Panel Discussion at the Cleveland Clinic 2019 Medical Innovation Summit
Oct 7, 2019 07:30 AM VIVUS Announces Acceptance of Qsymia Decentralized Marketing Authorization Application in Europe
Oct 3, 2019 07:30 AM VIVUS Initiates Pay Down of Secured Debt and Announces Management Changes
Aug 28, 2019 07:30 AM VIVUS to Present at Upcoming Conferences
Aug 27, 2019 07:30 AM VIVUS to Share Qsymia® Safety and Efficacy Data with a Global Audience at ICOMES & AOCO 2019
Aug 20, 2019 07:30 AM New Pilot Clinical Study Results Demonstrate that Addition of VIVUS’ Qsymia® to Gastric Sleeve Surgery Significantly Improves Weight Loss Compared with Surgery Alone
Aug 6, 2019 04:05 PM VIVUS Reports Second Quarter 2019 Financial Results
Aug 5, 2019 07:30 AM VIVUS Announces Approval of Qsymia® in the Republic of Korea
Jul 23, 2019 07:30 AM VIVUS to Host Second Quarter Business Update and Financial Results Conference Call on Tuesday, August 6, 2019
Jun 26, 2019 04:05 PM VIVUS and Nordmark Amend Contract Manufacturing Agreement to Supply Current and Future Demand for PANCREAZE®
Jun 11, 2019 07:30 AM VIVUS Reduces Barrier to Achieving Healthy Weight Goals With Launch of Online Platform to Purchase Qsymia®
May 28, 2019 07:30 AM VIVUS Initiates Phase Four Safety and Efficacy Study of Qsymia® in Obese Adolescents
May 15, 2019 07:53 AM VIVUS Partners with HarborPath Direct to Facilitate Access to PANCREAZE® for Patients Without Health Insurance
Apr 30, 2019 04:05 PM VIVUS Reports First Quarter 2019 Financial Results
Apr 16, 2019 07:30 AM VIVUS to Host First Quarter Business Update and Financial Results Conference Call on Tuesday, April 30, 2019
Mar 14, 2019 07:30 AM VIVUS Announces Marketing Approval of Avanafil in the Russian Federation for the Treatment of Erectile Dysfunction
Feb 26, 2019 04:05 PM VIVUS Reports Fourth Quarter 2018 Financial Results
Feb 26, 2019 04:05 PM VIVUS Reports Fourth Quarter 2018 Financial Results
Feb 13, 2019 07:30 AM VIVUS to Host Fourth Quarter and Full Year Business Update and Financial Results Conference Call on Tuesday, February 26, 2019
Feb 13, 2019 07:30 AM VIVUS to Host Fourth Quarter and Full Year Business Update and Financial Results Conference Call on Tuesday, February 26, 2019
Feb 4, 2019 04:00 PM VIVUS Announces Date of 2019 Annual Meeting
Jan 14, 2019 07:30 AM Data Supporting the Cardiovascular Safety of VIVUS’ Qsymia® Published in The Journal of Clinical Endocrinology & Metabolism
Dec 27, 2018 07:30 AM VIVUS to Present at Biotech Showcase on January 9, 2019
Dec 27, 2018 07:30 AM VIVUS to Present at Biotech Showcase on January 9, 2019
Pages: 1 2 3 »» Last Page

Back to VVUS Stock Lookup